William Blair & Company
TAK icon

William Blair & Company’s Takeda Pharmaceutical TAK Stock Holding History

William Blair & Company’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Buy
+10,703
New +$177K ﹤0.01% 1602
2026
Q1 		– Sell
-10,011
Closed -$156K – 2002
2025
Q4 		$156K Buy
+10,011
New +$143K ﹤0.01% 1508
2025
Q3 		– Sell
-10,306
Closed -$159K – 1906
2025
Q2 		$159K Sell
10,306
-317
-3% -$4.68K ﹤0.01% 1455
2025
Q1 		$158K Sell
10,623
-1,576
-13% -$22.1K ﹤0.01% 1437
2024
Q4 		$162K Buy
12,199
+913
+8% +$12.5K ﹤0.01% 1477
2024
Q3 		$160K Sell
11,286
-840
-7% -$11.9K ﹤0.01% 1476
2024
Q2 		$157K Sell
12,126
-523
-4% -$6.92K ﹤0.01% 1452
2024
Q1 		$176K Buy
12,649
+777
+7% +$11.3K ﹤0.01% 1427
2023
Q4 		$169K Buy
11,872
+203
+2% +$2.88K ﹤0.01% 1426
2023
Q3 		$181K Hold
11,669
– – ﹤0.01% 1409
2023
Q2 		$183K Sell
11,669
-55
-0.5% -$901 ﹤0.01% 1421
2023
Q1 		$193K Sell
11,724
-55
-0.5% -$876 ﹤0.01% 1410
2022
Q4 		$184K Buy
11,779
+3
+0% +$42 ﹤0.01% 1383
2022
Q3 		$153K Buy
11,776
+782
+7% +$10.9K ﹤0.01% 1441
2022
Q2 		$154K Sell
10,994
-1,031
-9% -$14.7K ﹤0.01% 1468
2022
Q1 		$172K Buy
12,025
+390
+3% +$5.73K ﹤0.01% 1551
2021
Q4 		$159K Sell
11,635
-1,287
-10% -$18.1K ﹤0.01% 1626
2021
Q3 		$212K Buy
12,922
+96
+0.7% +$1.61K ﹤0.01% 1470
2021
Q2 		$216K Sell
12,826
-423
-3% -$7.2K ﹤0.01% 1473
2021
Q1 		$242K Buy
13,249
+336
+3% +$6.04K ﹤0.01% 1410
2020
Q4 		$235K Sell
12,913
-1,445
-10% -$25.4K ﹤0.01% 1362
2020
Q3 		$256K Sell
14,358
-534
-4% -$9.72K ﹤0.01% 1198
2020
Q2 		$267K Buy
14,892
+880
+6% +$15.8K ﹤0.01% 1141
2020
Q1 		$213K Buy
14,012
+524
+4% +$9.5K ﹤0.01% 1146
2019
Q4 		$266K Sell
13,488
-3,556
-21% -$68K ﹤0.01% 1219
2019
Q3 		$293K Buy
17,044
+1,660
+11% +$28.7K ﹤0.01% 1124
2019
Q2 		$272K Sell
15,384
-806
-5% -$14.7K ﹤0.01% 1183
2019
Q1 		$330K Buy
+16,190
New +$326K ﹤0.01% 1114

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

William Blair & Company's TAK Position: Q2 2026 in Review

William Blair & Company opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 10,703 shares worth $172K. The stake represents ﹤0.01% of the portfolio and ranks #1602 among its holdings. This is a return to the name: William Blair & Company previously reported a position in TAK as recently as Q4 2025.

William Blair & Company first reported a position in TAK in Q1 2019 and has held it in 28 quarters since. The position peaked at $330K in Q1 2019. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • William Blair & Company held 10,703 shares of Takeda Pharmaceutical worth $172K as of Q2 2026.
  • Takeda Pharmaceutical was a new William Blair & Company position in Q2 2026.
  • Takeda Pharmaceutical made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1602 holding.
  • William Blair & Company first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 28 quarters since.
  • William Blair & Company's Takeda Pharmaceutical position peaked at $330K in Q1 2019.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.